These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35322520)

  • 21. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.
    Boessen R; van der Baan F; Groenwold R; Egberts A; Klungel O; Grobbee D; Knol M; Roes K
    Pharm Stat; 2013; 12(6):366-74. PubMed ID: 24214896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Group sequential designs for stepped-wedge cluster randomised trials.
    Grayling MJ; Wason JM; Mander AP
    Clin Trials; 2017 Oct; 14(5):507-517. PubMed ID: 28653550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints.
    Uozumi R; Yada S; Kawaguchi A
    BMC Med Res Methodol; 2019 Jul; 19(1):159. PubMed ID: 31331277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of Predictive Analyses for Interim Decisions in Clinical Trials.
    Avalos-Pacheco A; Ventz S; Arfè A; Alexander BM; Rahman R; Wen PY; Trippa L
    JCO Precis Oncol; 2023 Feb; 7():e2200606. PubMed ID: 36848613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
    Wathen JK; Thall PF
    Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Futility for subgroup analyses in the adaptive signature design.
    Callegaro A
    Stat Methods Med Res; 2019 Mar; 28(3):953-961. PubMed ID: 29179654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs.
    Ballarini NM; Burnett T; Jaki T; Jennison C; König F; Posch M
    Stat Med; 2021 May; 40(12):2939-2956. PubMed ID: 33783020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trial monitoring via a futility criterion for interim results on a count data endpoint and a continuous endpoint.
    Quan H; Kang T; Fan C; Lu X; Chen X; Luo X; Wei L
    Contemp Clin Trials; 2021 Apr; 103():106316. PubMed ID: 33571688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimized adaptive enrichment designs for three-arm trials: learning which subpopulations benefit from different treatments.
    Steingrimsson JA; Betz J; Qian T; Rosenblum M
    Biostatistics; 2021 Apr; 22(2):283-297. PubMed ID: 31420983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
    Shimura M; Maruo K; Gosho M
    Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation.
    Herrmann C; Pilz M; Kieser M; Rauch G
    Stat Med; 2020 Jul; 39(15):2067-2100. PubMed ID: 32249968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving sample size recalculation in adaptive clinical trials by resampling.
    Herrmann C; Kluge C; Pilz M; Kieser M; Rauch G
    Pharm Stat; 2021 Nov; 20(6):1035-1050. PubMed ID: 33792167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.